.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,468,743

« Back to Dashboard

Claims for Patent: 5,468,743

Title: Imidazo[2,1-b]benzazepine derivatives, compositions and method of use
Abstract:The present invention is concerned with novel imidazo[2, 1-b][3]benzazepines of formula ##STR1## the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein each of the dotted lines independently represents an optional bond; R.sup.1 represents hydrogen, halo, C.sub.1-4 alkyl or C.sub.1-4 alkyloxy; R.sup.2 represents hydrogen, halo, C.sub.1-4 alkyl or C.sub.1-4 alkyloxy; R.sup.3 represents hydrogen, C.sub.1-4 alkyl, ethenyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, C.sub.1-4 alkyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, hydroxyC.sub.1-4 alkyl, formyl or hydroxycarbonyl; R.sup.4 represents hydrogen, C.sub.1-4 alkyl, hydroxyC.sub.1-4 alkyl, phenyl or halo; R.sup.5 represents hydrogen, C.sub.1-4 alkyl or halo; L represents hydrogen; C.sub.1-6 alkyl; C.sub.1-6 alkyl substituted with one substituent selected from the group consisting of hydroxy, halo, C.sub.1-4 alkyloxy, hydroxycarbonyl, C.sub.1-4 alkyloxycarbonyl, C.sub.1-4 alkyloxycarbonyl-C.sub.1-4 alkyloxy, hydroxycarbonylC.sub.1-4 alkyloxy, C.sub.1-4 alkyloxycarbonylamino, C.sub.1-4 alkylaminocarbonyl, C.sub.1-4 alkylaminocarbonylamino, C.sub.1-4 alkylaminothiocarbonylamino, aryl, aryloxy and arylcarbonyl; C.sub.1-6 alkyl substituted with both hydroxy and aryloxy; C.sub.3-6 alkenyl; C.sub.3-6 alkenyl substituted with aryl; or, L represents a radical of formula --Alk--Y--Het.sup.1 (a-1),--Alk--NH--CO--Het.sup.2 (a-2)or --Alk--Het.sup.3 (a-3); provided that 6,11-dihydro-11-(4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine is ecxluded, which are useful antiallergic compounds. Compositions comprising said compounds, methods of using and processes for preparing the same.
Inventor(s): Janssens; Frans E. (Bonheiden, BE), Diels; Gaston S. M. (Ravels, BE), Leenaerts; Joseph E. (Rijkevorsel, BE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:08/142,474
Patent Claims: 1. A compound of the formula: ##STR159## a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein:

each of the dotted lines independently represents an optional bond;

R.sup.1 represents hydrogen, halo, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy;

R.sup.2 represents hydrogen, halo, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy;

R.sup.3 represents hydrogen, C.sub.1-4 alkyl, ethenyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, C.sub.1-4 alkyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, hydroxyC.sub.1-4 alkyl, formyl or hydroxycarbonyl;

R.sup.4 represents hydrogen, C.sub.1-4 alkyl, hydroxyC.sub.1-4 alkyl, phenyl or halo;

R.sup.5 represents hydrogen, C.sub.1-4 alkyl or halo;

L represents C.sub.1-6 alkyl; C.sub.1-6 alkyl substituted with one substituent selected from the group consisting of hydroxy, halo,

C.sub.1-4 alkyloxy, hydroxycarbonyl, C.sub.1-4 alkyloxycarbonyl, C.sub.1-4 alkyloxycarbonylC.sub.1-4 alkyloxy, hydroxycarbonylC.sub.1-4 alkyloxy, C.sub.1-4 alkyloxycarbonylamino, C.sub.1-4 alkylaminocarbonyl, C.sub.1-4 alkylaminocarbonylamino, C.sub.1-4 alkylaminothiocarbonylamino, aryl, aryloxy and arylcarbonyl; C.sub.1-6 alkyl substituted with both hydroxy and aryloxy; C.sub.3-6 alkenyl; C.sub.3-6 alkenyl substituted with aryl;

wherein each aryl is phenyl or phenyl substituted with halo, cyano, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkyloxy, aminocarbonyl or phenyl substituted with C.sub.1-4 alkyloxycarbonyl or hydroxycarbonyl; or

L represents a radical of the formula:

Alk represents C.sub.1-4 alkanediyl;

Y represents O, S or NH;

Het.sup.1, Het.sup.2 and Het.sup.3 each represent:

furanyl, thienyl, oxazolyl, thiazolyl or imidazolyl each optionally substituted with one or two C.sub.1-4 alkyl substituents;

pyrrolyl or pyrazolyl optionally substituted with formyl, hydroxyC.sub.1-4 alkyl, hydroxycarbonyl, C.sub.1-4 alkyloxycarbonyl or with one or two C.sub.1-4 alkyl substituents;

thiadiazolyl or oxadiazolyl optionally substituted with amino or C.sub.1-4 alkyl;

pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl each optionally substituted with C.sub.1-4 alkyl, C.sub.1-4 alkyloxy, amino, hydroxy or halo; or

imidazo[4,5-c]pyridin-2-yl;

and Het.sup.3 may also represent a member selected from the group consisting of:

(a) 4,5-dihydro-5-oxo-1H-tetrazolyl substituted with C.sub.1-4 alkyl;

(b) 2-oxo-3-oxazolidinyl;

(c) 2,3-dihydro-2-oxo-1H-benzimidazol1-yl; and

(d) a radical of the formula: ##STR160## wherein: R.sup.6 represents hydrogen or C.sub.1-4 alkyl; and

A-Z represents --S--CH.dbd.CH--, --S--CH.sub.2 --CH.sub.2 --, --S--CH.sub.2 --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--CH.dbd.CH--, --CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 --, --N(CH.sub.3)--C(CH.sub.3).dbd.CH-- or --CH.dbd.C (CH.sub.3)--O--.

2. A compound according to claim 1 wherein L is C.sub.1-4 alkyl or C.sub.1-4 alkyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl.

3. A compound according to claim 1 wherein:

R.sup.3 represents hydrogen, C.sub.1-4 alkyl, formyl, hydroxyC.sub.1-4 alkyl or hydroxycarbonyl;

R.sup.4 represents hydrogen, halo or hydroxyC.sub.1-4 alkyl; and

L represents C.sub.1-4 alkyl, haloC.sub.1-4 alkyl, hydroxycarbonylC.sub.1-4 alkyl, C.sub.1-4 alkyloxycarbonylC.sub.1-4 alkyl, C.sub.1-4 alkyloxycarbonylaminoC.sub.1-4 alkyl, arylC.sub.1-4 alkyl, propenyl, or

L is a radical of the formula:

Het.sup.1, Het.sup.2 and Het.sup.3 each represent furanyl oxazolyl, or thiazolyl each optionally substituted with C.sub.1-4 alkyl; thiadiazolyl optionally substituted with amino; pyridinyl; pyrimidinyl optionally substituted with hydroxy; or imidazo[4,5-c]pyridin-2-yl;

or Het.sup.3 may also represent a radical of the formula (b-2): ##STR161##

4. A compound according to claim 3 wherein

R.sup.1 represents hydrogen or halo;

R.sup.2 represents hydrogen, halo or C.sub.1-4 alkyloxy; and

L represents hydrogen, C.sub.1-4 alkyl, haloC.sub.1-4 alkyl, hydroxycarbonylC.sub.1-4 alkyl, C.sub.1-4 alkyloxycarbonylC.sub.1-4 alkyl, or a radical of formula (a-1), wherein Y represents NH.

5. A compound according to claim 1 wherein said compound is selected from the group consisting of

5,6-dihydro-11-(1-methyl-4-piperidinylidene)-11H-imidazo[2,1-b][3 ]benzazepine;

9-fluoro-6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5H-imidazo[2,1-b][3] benzazepine;

11-(1-methyl-4-piperidinylidene)-11H-imidazo[2,1-b][3]benzazepine;

6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepi ne-3-methanol;

8-fluoro-6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5H-imidazo[2,1-b][3] benzazepine;

6,11-dihydro-11-(1-methyl-4-piperidinylidene)- 5H-imidazo[2,1-b][3]benzazepine-3-carboxaldehyde;

6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepi ne-3carboxylic acid;

7-fluoro-6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5H-imidazo[2,1-b][3] benzazepine; and

4-(8-fluoro-5,6-dihydro-11H-imidazo[2,1-b][3]benzazepin-11-ylidene)-1-piper idinepropanoic acid dihydrate.

6. A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound as defined in claim 1 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound as defined in claim 2 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound as defined in claim 3 and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound as defined in claim 4 and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound as defined in claim 5 and a pharmaceutically acceptable carrier.

11. A method of treating allergic conditions in warm blooded animals which comprises administering to warm blooded animals suffering from allergic conditions an effective anti-allergic amount of a compound as defined in claim 1.

12. A method of treating allergic conditions in warm blooded animals which comprises administering to warm blooded animals suffering from allergic conditions an effective anti-allergic amount of a compound as defined in claim 2.

13. A method of treating allergic conditions in warm blooded animals which comprises administering to warm blooded animals suffering from allergic conditions an effective anti-allergic amount of a compound as defined in claim 3.

14. A method of treating allergic conditions in warm blooded animals which comprises administering to warm blooded animals suffering from allergic conditions an effective anti-allergic amount of a compound as defined in claim 4.

15. A method of treating allergic conditions in warm blooded animals which comprises administering to warm blooded animals suffering from allergic conditions an effective anti-allergic amount of a compound as defined in claim 5.

16. A compound of the formula: ##STR162## an acid addition salt thereof or a stereochemically isomeric form thereof, wherein each of the dotted lines independently represents an optional bond, and wherein:

R.sup.1 represents hydrogen, halo, C.sub.1-4 alkyl or C.sub.1-4 alkyloxy;

R.sup.2 represents hydrogen, halo, C.sub.1-4 alkyl or C.sub.1-4 alkyloxy;

R.sup.3 represents hydrogen, C.sub.1-4 alkyl, ethenyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, C.sub.1-4 alkyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, hydroxyC.sub.1-4 alkyl, formyl or hydroxycarbonyl;

R.sup.4 represents hydrogen, C.sub.1-4 alkyl, hydroxyC.sub.1-4 alkyl, phenyl or halo;

R.sup.5 represents hydrogen, C.sub.1-4 alkyl or halo; and

Q represents phenyloxycarbonyl, or C.sub.1-6 alkyl substituted with a member selected from the group consisting of halo, cyano, amino, isothiocyanato, (4-amino-3-pyridinyl)aminothiocarbonylamino, (CH.sub.3 O).sub.2 CH--CH.sub.2 --NH--C(.dbd.NCH.sub.3)--NH--, and methylsulfonyloxy.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc